NASDAQ:NDRA ENDRA Life Sciences Q3 2026 Earnings Date & Estimates $4.89 -0.21 (-4.12%) As of 10:58 AM Eastern This is a fair market value price provided by Massive. Learn more. ENDRA Life Sciences is estimated to report Q3 2026 earnings on Friday, November 13, 2026. The conference call is scheduled for 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 13, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from ENDRA Life Sciences in Q3 2026ENDRA Life Sciences is expected to post earnings of -$0.84 per share on revenue of $0.10 million. In the same quarter a year earlier ENDRA Life Sciences reported -$1.75 per share. ENDRA Life Sciences last reported on August 14, 2026, posting -$0.63 per share and beating the -$0.84 consensus estimate. ENDRA Life Sciences has beaten the consensus EPS estimate in 4 of its last 5 quarters.Consensus EstimatesConsensus EPS-$0.84Expected Revenue$0.10 millionPrior-Year EPS-$1.75Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.63 (Beat by +$0.21)EPS Beat Rate4 of last 5 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report ENDRA Life Sciences Q3 2026 Earnings FAQ When does ENDRA Life Sciences report Q3 2026 earnings? ENDRA Life Sciences (NASDAQ:NDRA) is estimated to report Q3 2026 earnings on Friday, November 13, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is ENDRA Life Sciences' Q3 2026 earnings call? ENDRA Life Sciences' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for ENDRA Life Sciences? Analysts expect ENDRA Life Sciences to post earnings of -$0.84 per share for Q3 2026. How much revenue is ENDRA Life Sciences expected to report? The consensus revenue estimate for ENDRA Life Sciences is $0.10 million for Q3 2026. ENDRA Life Sciences Earnings HeadlinesENDRA Shares Rise 12% As Q2 Loss Swings To Profit; Advances Noble Africa MergerSeptember 4, 2026 | rttnews.comENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 17, 2026 | finance.yahoo.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing December 8th.October 16 at 1:00 AM | Paradigm Press (Ad)ASP Isotopes to Host Investor Meetings at Citi’s 2026 Natural Resources ConferenceAugust 5, 2026 | quiverquant.comQASP Isotopes Announces Capital Markets Day in London on September 8, 2026July 28, 2026 | quiverquant.comQENDRA Life Sciences (NDRA) Gets a Buy from AscendiantJuly 25, 2026 | theglobeandmail.comSee More ENDRA Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ENDRA Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ENDRA Life Sciences and other key companies, straight to your email. Email Address About ENDRA Life SciencesENDRA Life Sciences (NASDAQ:NDRA) Corp. (NASDAQ: NDRA) is a medical technology company developing noninvasive diagnostic imaging systems. The company’s primary technology is Thermo-Acoustic Enhanced UltraSound (TAEUS), a platform designed to expand the capabilities of conventional ultrasound by using radiofrequency energy and ultrasound imaging to characterize tissue properties. ENDRA is initially focused on applying TAEUS to the assessment of liver fat, including fatty liver disease. Its system is intended to provide quantitative information about hepatic steatosis and potentially other tissue characteristics without requiring an invasive biopsy or the use of more costly imaging modalities. The technology is designed to work with existing ultrasound equipment, which could support broader adoption in clinical settings. Based in Ann Arbor, Michigan, ENDRA has worked with medical-device and imaging-industry partners to advance the development and validation of its technology. TAEUS remains a medical-device development program and may require additional regulatory clearances and clinical validation before broader commercial use. The company is led by Chief Executive Officer Francois Michelon.View ENDRA Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure3 Stocks to Watch as Wall Street Wealth Fuels Consumer SpendingASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could Deepen Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
